• Michele Simonato, Amy R Brooks-Kayal, Jerome Engel, Aristea S Galanopoulou, Frances E Jensen, Solomon L Moshé, Terence J O'Brien, Asla Pitkanen, Karen S Wilcox, and Jacqueline A French.
• Department of Medical Sciences (Section of Pharmacology), University of Ferrara, and National Institute of Neuroscience, Ferrara, Italy.
• Lancet Neurol. 2014 Sep 1; 13 (9): 949960949-60.

AbstractTranslation of successful target and compound validation studies into clinically effective therapies is a major challenge, with potential for costly clinical trial failures. This situation holds true for the epilepsies-complex diseases with different causes and symptoms. Although the availability of predictive animal models has led to the development of effective antiseizure therapies that are routinely used in clinical practice, showing that translation can be successful, several important unmet therapeutic needs still exist. Available treatments do not fully control seizures in a third of patients with epilepsy, and produce substantial side-effects. No treatment can prevent the development of epilepsy in at-risk patients or cure patients with epilepsy. And no specific treatment for epilepsy-associated comorbidities exists. To meet these demands, a redesign of translational approaches is urgently needed.Copyright © 2014 Elsevier Ltd. All rights reserved.

12 keywords...

hide…